Belfast-based contract research organisation Fusion Antibodies plc (AIM: FAB) announced on Wednesday that it has expanded its collaboration agreement with the US National Cancer Institute (NCI) to include the humanisation of several existing camelid nanobodies developed by NCI.

Camelid nanobodies, derived from camel species, are increasingly valuable in bi-specific therapies and Chimeric Antigen Receptor (CAR) therapies.

This extension builds on the existing partnership where Fusion provides access to its OptiMAL platform for discovering novel antibodies targeting cancer.

NCI, a leading US federal agency for cancer research, collaborates with Fusion to enhance therapeutic antibody development.

Fusion Antibodies specialises in pre-clinical antibody discovery and engineering, serving global pharmaceutical and diagnostic companies.